Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773788 | 0.88 | AKR1B1 (0.32) | LMNAL3MBTL1AKR1B1 | |
| SCHEMBL3851271 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2316300 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL599665 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL15754346 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL8486 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL8718435 | 0.80 | LMNA (0.39) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL3138864 | 0.76 | MGAM (0.38) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL1921547 | 0.76 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL3507130 | 0.76 | PTPN1 (0.36) | LMNAL3MBTL1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130434-A1 | Hexose Compounds to Treat Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1986660-A4 | HEXOSE COMPOUNDS TO TREAT CANCER | UNIV TEXAS (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1986660-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007101148-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130434-A1 | Hexose Compounds to Treat Cancer | MAN2A1, FBP1, MAN2B1 | LMNA 4494/4885L3MBTL1 2549/4885TDP1 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.